

Predictors of Incomplete Vaccination Schedules Among Children and Adolescents in San Diego County During the COVID-19 Pandemic

Presented at San Diego Immunization Coalition Meeting April 5, 2023

Danelle Wallace, MPH Senior Epidemiologist Epidemiology & Immunization Services Branch Public Health Services



Introduction





Danelle Wallace, MPH Senior Epidemiologist Vaccine Preventable Disease
 (VPD) and Immunization
 Epidemiologist at the County of
 San Diego

Background



- Incomplete childhood vaccination can occur due to a variety of reasons, including:
 - Parental consent, and
 - Access to healthcare.
- An incomplete vaccination schedule is when an individual is partially vaccinated against a disease because they received some, but not all, recommended shots.
 - This primarily concerns vaccination schedules with more than one recommended shot.
- On March 13, 2020, the United States declared a nationwide state of emergency as the novel coronavirus 2019 (COVID-19) rapidly spread.
 - The state of California followed suit with stay-at-home orders (SAHO) requiring the restriction of non-essential movement and business on March 17, 2020.

Background (cont.)



- The Coronavirus disease 2019 (COVID-19) pandemic changed the priorities of healthcare facilities.
- Caused many healthcare systems to stop performing routine screenings and health care appointments.
- Altered healthcare hours, lockdowns, and public fear to refer to medical centers caused a significant reduction in routine appointments.¹

Background (cont.)



- Although healthcare services remained opened, there were decreases in routine vaccination screening and administration.²
- Some states observed relatively slow rebounds in childhood vaccination uptake after local restrictions eased, but rates struggled to return to pre-pandemic levels.³

Childhood Vaccines



- Many routine childhood
 vaccines have multiple doses
 and varied schedules.⁵
- Focus on inactivated polio
 (IPV), measles mumps and
 rubella (MMR), and varicella
 (VAR) vaccines due to gaps
 between doses.

| Vaccine | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | 18 mos | 19–23 mos | 2–3 yrs | 4–6 yrs | 7–10 yrs | 11–12 yrs | 13–15 yrs | 16 yrs | 17-18 y |
|--|---------|-------------------|----------------------|----------------------|----------------------|-------|--------------------------------------|----------------------------|-------------|-----------|--------------|---------------------------|----------|--------------|--------------|----------------------|---------|
| Hepatitis B (HepB) | 1ª dose | 4 2 nd | dose> | | • | | 3 rd dose | | , | | | | | | | | |
| Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series) | | | 1 st dose | 2 nd dose | See Notes | | | | | | | | | | | | |
| Diphtheria, tetanus, acellular pertussis DTaP <7 yrs) | | | 1ª dose | 2 nd dose | 3 rd dose | | | ∢ 4 th c | loseÞ | | | 5 th dose | | | | | |
| Haemophilus influenzae type b (Hib) | | | 1 st dose | 2 nd dose | See Notes | | <a>3rd or 4 See 1 | th dose | | | | | | | | | |
| Pneumococcal conjugate (PCV13) | | | 1" dose | 2 nd dose | 3 rd dose | | ∢ 4 th c | lose —> | | | | | | | | | |
| nactivated poliovirus IPV <18 yrs) | | | 1 st dose | 2 nd dose | • | | 3 rd dose | | | | | 4 th dose | | | | | |
| nfluenza (IIV4) | | | | | | | A | nnual vacci | nation 1 or | 2 doses | | | | Annua | lvaccination | 1 dose on | ly |
| Influenza (LAIV4) | | | | | | | | | | | Annua 1 o | l vaccinatio r 2 doses | n 000 - | Annua | lvaccination | 1 dose on | ly |
| Measles, mumps, rubella (MMR) | | | | | See M | lotes | ∢ 1 [#] c | loseÞ | | | | 2 nd dose | | | | | |
| Varicella (VAR) | | | | | | | ∢ 1* c | lose | | | | 2 nd dose | | | | | |
| Hepatitis A (HepA) | | | | | See M | lotes | | 2-dose serie | s, See Note | s | | | | | | | |
| Fetanus, diphtheria, acellular pertussis Tdap ≥7 yrs) | | | | | | | | | | | | | | 1 dose | | | |
| Human papillomavirus (HPV) | | | | | | | | | | | | | | See Notes | | | |
| Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) | | | | | | | | See Notes | | | | | | 1" dose | | 2 nd dose | |
| Meningococcal B (MenB-4C, MenB- FHbp) | | | | | | | | | | | | | | | See No | tes | |
| Pneumococcal polysaccharide (PPSV23) | | | | | | | | | | | | | | See Notes | | | |
| Dengue (DEN4CYD: 9-16 vrs) | | | | | | | | | | | | | Se | ropositive i | n endemic a | reas only | |

Research Questions



- What proportion of children and adolescents have incomplete IPV, MMR, and/or VAR series?
- Are there demographic and/or regional disparities regarding incompleteness?

Study Population



- Data were obtained from the San Diego Immunization Registry (SDIR).
- SDIR was the regional immunization registry for the County of San Diego until the switch to the California Immunization Registry (CAIR2) on April 25, 2022.
- Note that California is not a mandatory reporting state, so not all providers reported to SDIR.
- Records were subset to ages between 6 -19 years old by 12/31/2021.
- Observations, who were ineligible to receive their next dose due to CDC interval guidelines, were removed from the analysis.

Methods – Variables



- Variables of interest were age, gender, race or ethnicity, zip code, and IPV, MMR, and VAR.
- Zip codes were matched with the six San Diego County region boundaries.
 - Zip codes outside San Diego County were collapsed to variable "Out of jurisdiction" (OOJ).
 - Most recent zip code on record was used before sub-setting the data.
- Variables for IPV, MMR, and VAR were created to signify the highest dose received in each schedule.
 - Incompleteness was determined with a binary variable by categorizing the highest dose received as either the last dose of the schedule (complete) or not the last dose of the schedule (incomplete).
 - CDC vaccination schedules and interval guidelines were used to determine incompleteness.⁶

Methods – Statistical Analyses 🍩 🕅 SAN MEEL

- IBM SPSS Statistics Version 24 was used for data cleaning, descriptive statistics, and analysis.
- Pearson's correlations were used to identify potential collinearity.
- A X^2 analysis tested independence of incomplete vaccination series from gender.
- Kruskal-Wallis tests determined within-group differences for the race/ethnicity and region variables.
- Age was inversely transformed to allow for interpretation of odds as age values decreased.
- Adjusted and unadjusted models used binary logistic regression to determine odds of having an incomplete vaccination series.

Methods – Study Population



- There were over 500,000 children and adolescents included in the analysis.
- More than half of the study population were recorded as either Hispanic or White even with the inclusion of missing racial data (26%).
- Each of the six County HHSA Regions contained approximately 15% of the study population except for North Inland (19%) and South (20%).
- Overall rates of incomplete vaccination series were similar between MMR (20%) and VAR (21%) series, while the IPV rate was higher (27%).

Results – Descriptive Statistics () Medde Statistics ()

| Table 1. Descriptive statistics | | | | | | |
|---------------------------------|------------|--|--|--|--|--|
| Variable | Value | | | | | |
| Total observations (n) | 508,965 | | | | | |
| Years of age (mean ± SD) | 12.4 ± 3.8 | | | | | |
| Gender (%) | | | | | | |
| Male | 50 | | | | | |
| Missing | 1.7 | | | | | |
| Race (%) | | | | | | |
| AI/AN | 0.3 | | | | | |
| Asian | 6 | | | | | |
| Black | 3.6 | | | | | |
| Hispanic | 28.8 | | | | | |
| NH/PI | 0.4 | | | | | |
| Other | 10.9 | | | | | |
| White | 23.7 | | | | | |
| Missing | 26.4 | | | | | |
| HHSA Region (%) | | | | | | |
| Central | 14.9 | | | | | |
| East | 15.8 | | | | | |
| North Central | 15 | | | | | |
| North Coastal | 15.3 | | | | | |
| North Inland | 19.1 | | | | | |
| South | 20 | | | | | |
| PV (%) | | | | | | |
| Incomplete | 25.5 | | | | | |
| Missing | 3.6 | | | | | |
| MMR (%) | | | | | | |
| Incomplete | 18.5 | | | | | |
| Missing | 6.4 | | | | | |
| VAR (%) | | | | | | |
| Incomplete | 19.7 | | | | | |
| Missing | 7.1 | | | | | |

- More than half of the study population were recorded as either Hispanic or White (26%).
- North Inland (19%) and South (20%) Regions had slightly higher percentages of included individuals.
- Rates of incomplete vaccination series were lower among MMR (18%) and VAR (19%) series than the IPV rate (25%).

Results – Incomplete Vaccinations

| Table 2. Incomplete vaccination prevalence by vaccination series | | | | | | |
|--|---------------|---------------------------|------------|------------|--|--|
| | | Incomplete Series | | | | |
| | All completed | IPV | MMR | VAR | | |
| 'ears of age (mean ± SD) | 12.5 ± 3.8 | 12.0 ± 3.8 | 11.9 ± 3.7 | 12.1 ± 3.8 | | |
| | | Incomplete Prevalence (%) | | | | |
| /ariable | | IPV | MMR | VAR | | |
| /lale | | 26.2 | 19.3 | 20.8 | | |
| emale | | 26 | 19.9 | 21.3 | | |
| lace | | | | | | |
| AI/AN | | 23.1 | 16.1 | 16.8 | | |
| Asian | | 26.1 | 19.7 | 21.4 | | |
| Black | | 25.6 | 16.5 | 18.1 | | |
| Hispanic | | 17.3 | 14.2 | 15.4 | | |
| NH/PI | | 21.4 | 15.4 | 16.7 | | |
| Other | | 27.3 | 20.7 | 22.1 | | |
| White | | 28.5 | 21.5 | 22.9 | | |
| HSA Region | | | | | | |
| Central | | 22.6 | 15.2 | 16.7 | | |
| East | | 31.2 | 21.3 | 22.9 | | |
| North Central | | 25.4 | 21.3 | 23.3 | | |
| North Coastal | | 27.3 | 21.2 | 22.2 | | |
| North Inland | | 27.7 | 21.2 | 22.2 | | |
| South | | 24.5 | 18.6 | 20.1 | | |



 Incompleteness of vaccination series was similar for males and females

White children consistently
had higher rates of incomplete
vaccination series for all three
antigens

Results – Unadjusted Model 🍩 | 🖾 Live Well

| Table 3. Unadjusted associations by vaccination series | | | | | | | |
|--|--------------------|--|--------------------|--|--|--|--|
| | | Outcome | | | | | |
| | Incomplete IPV | Incomplete MMR | Incomplete VAR | | | | |
| Variable | Estimat | Estimated Odds (99% Confidence Interval) | | | | | |
| Age (decrease 1 year) | 1.03 (1.03 – 1.04) | 1.05 (1.05 – 1.05) | 1.03 (1.03 – 1.04) | | | | |
| Gender (Female) | 0.99 (0.97 – 1.01) | 1.04 (1.02 – 1.05) | 1.03 (1.01 – 1.05) | | | | |
| Race/ethnicity | | | | | | | |
| AI/NA | 0.75 (0.65 – 0.88) | 0.70 (0.59 – 0.84) | 0.68 (0.57 – 0.81) | | | | |
| Asian | 0.89 (0.86 – 0.92) | 0.90 (0.86 – 0.94) | 0.92 (0.88 – 0.95) | | | | |
| Black | 0.86 (0.83 – 0.91) | 0.72 (0.69 – 0.77) | 0.75 (0.71 – 0.79) | | | | |
| Hispanic | 0.53 (0.52 – 0.54) | 0.61 (0.59 – 0.62) | 0.61 (0.60 – 0.63) | | | | |
| NH/PI | 0.68 (0.59 – 0.78) | 0.66 (0.57 – 0.78) | 0.68 (0.58 – 0.79) | | | | |
| Other | 0.95 (0.92 – 0.97) | 0.95 (0.92 – 0.99) | 0.95 (0.92 – 0.98) | | | | |
| White | Reference | Reference | Reference | | | | |
| HHSA Region | | | | | | | |
| Central | Reference | Reference | Reference | | | | |
| East | 1.55 (1.51 – 1.60) | 1.51 (1.46 – 1.57) | 1.49 (1.44 – 1.54) | | | | |
| North Central | 1.16 (1.13 – 1.20) | 1.51 (1.46 – 1.57) | 1.52 (1.47 – 1.57) | | | | |
| North Coastal | 1.28 (1.24 – 1.32) | 1.50 (1.45 – 1.56) | 1.43 (1.38 – 1.48) | | | | |
| North Inland | 1.31 (1.27 – 1.35) | 1.51 (1.46 – 1.56) | 1.43 (1.38 - 1.48) | | | | |
| South | 1.11 (1.08 – 1.15) | 1.56 (1.51 – 1.62) | 1.26 (1.22 – 1.30) | | | | |

Results – Adjusted Model 🍩 | 🗺 LINE WELL

| Table 4. Adjusted associations by vaccination series | | | | | | | | |
|--|--------------------|--|--------------------|--|--|--|--|--|
| | | Outcome | | | | | | |
| | Incomplete IPV | Incomplete MMR | Incomplete VAR | | | | | |
| Variable | Estimate | Estimated Odds (99% Confidence Interval) | | | | | | |
| Age (decrease 1 year) | 1.07 (1.07 – 1.07) | 1.08 (1.08 – 1.09) | 1.06 (1.06 – 1.06) | | | | | |
| Race/ethnicity | | | | | | | | |
| AI/NA | 0.58 (0.33 – 1.01) | 0.58 (0.30 – 1.13) | 0.59 (0.32 – 1.12) | | | | | |
| Asian | 0.71 (0.63 – 0.81) | 0.55 (0.47 – 0.65) | 0.60 (0.52 – 0.70) | | | | | |
| Black | 1.02 (0.92 – 1.13) | 0.71 (0.63 – 0.81) | 0.80 (0.71 – 0.91) | | | | | |
| Hispanic | 0.53 (0.49 – 0.58) | 0.63 (0.57 – 0.69) | 0.65 (0.59 – 0.72) | | | | | |
| NH/PI | 0.59 (0.40 – 0.88) | 0.70 (0.45 – 1.07) | 0.64 (0.42 – 0.99) | | | | | |
| Other | 0.83 (0.75 – 0.92) | 0.82 (0.73 – 0.92) | 0.83 (0.74 – 0.94) | | | | | |
| White | Reference | Reference | Reference | | | | | |
| HHSA Region | | | | | | | | |
| Central | Reference | Reference | Reference | | | | | |
| East | 1.32 (1.22 – 1.43) | 1.28 (1.17 – 1.41) | 1.31 (1.20 – 1.44) | | | | | |
| North Central | 0.73 (0.67 – 0.79) | 0.83 (0.75 – 0.91) | 0.87 (0.79 – 0.95) | | | | | |
| North Coastal | 1.17 (1.08 – 1.27) | 1.34 (1.22 – 1.47) | 1.36 (1.24 – 1.49) | | | | | |
| North Inland | 1.28 (1.18 – 1.39) | 1.46 (1.33 – 1.60) | 1.44 (1.32 – 1.58) | | | | | |
| South | 1.12 (1.02 – 1.23) | 1.36 (1.22 – 1.51) | 1.35 (1.22 – 1.50) | | | | | |

Conclusion



- The association between decreasing age and increased odds of incomplete vaccination series can suggests that children eventually complete their vaccination series later into their adolescence.
 - Children transition into middle school and must meet school entrance requirements.
- Some racial differences and interactions were evident in modeling and could be used for health outreach and planning purposes.
- The high correlations of incompleteness between IPV, MMR, and VAR vaccination series suggests that many individuals had multiple incomplete series.
 - Providers have opportunities to vaccinate and bring children UTD.

References



- 1) Sabetkish, N. and Rahmani, A. The overall impact of COVID-19 on healthcare during the pandemic: A multidisciplinary point of view. *Health Sci Reports*, 2021 Oct. 1; 4(4):e386.
- American Academy of Pediatrics. (2020). *Guidance on providing pediatric well-care during COVID-19.* Retrieved April 15, 2022, from <u>https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-</u> <u>infections/clinical-guidance/guidance-on-providing-pediatric-well-care-during-covid-19</u>
- Langdon-Embry, M., Papadouka, V., Cheng, I., Almashhadani, M., Ternier, A., & Zucker, J. R. (2020). Notes from the field: rebound in routine childhood vaccine administration following decline during the COVID-19 pandemic - New York City, March 1 - June 27, 2020. *Morbidity and Mortality Weekly Report,* 69(30), 999-1001. doi:10.15585/mmwr.mm6930a3.
- 4) O'Leary, S. T., Trefren, L., Roth, H., Moss, A., Severson, R., & Kempe, A. (2021). Number of childhood and adolescent vaccinations administered before and after the COVID-19 outbreak in Colorado. *JAMA Pediatrics*, 175(3), 305-307. doi:10.1001/jamapediatrics.2020.4733.

References (cont.)



- 5) Centers for Disease Control and Prevention. (2022a). *Child and Adolescent Immunization Schedules*. Retrieved March 4, 2022, from Immunization Schedules: https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html.
- 6) Centers for Disease Control and Prevention. (2022b). Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind. Retrieved April 15, 2022, from Immunization Schedules: https://www.cdc.gov/vaccines/schedules/hcp/imz/catchup.html.

Acknowledgements



Dr. Wilma Wooten

- Dr. Elizabeth Hernandez
- Dr. Seema Shah
- Jeffrey Johnson



Christian Hicks (co-author)



Questions?

Danelle Wallace, MPH

Senior Epidemiologist

Epidemiology and Immunization Services Branch

DanelleRuth.Wallace@sdcounty.ca.gov

(619) 629-1698







